Introduction
Cognition is often impaired in multiple sclerosis (MS) and is a function of disease activity and progression in the early stages. Most patients suffer from attentional deficits at an early point [1] , and at least 40% of patients display minor cognitive impairments at the time of first diagno-medication was given with the exception of 1 patient who suffered a relapse during the test interval and received high-dose intravenous cortisone temporarily. The natalizumab infusions were given at a constant dose (300 mg) and at regular intervals (1 per month). One patient produced antibodies against natalizumab in the long run. Only 5 patients had to be given antibiotics and 2 patients analgesics for a limited time during the test period; the other concomitant medication remained unchanged (see table 1 ) .
Testing was performed at 3-month intervals, i.e. before the first infusion (point 0), after 3 (point 1) and after 6 months (point 2).
Tests included the SF-36 scale (short-form health survey with 36 questions), a scale for physical and mental fatigue, a depression scale (Beck depression inventory, BDI-II [ed 2]), and cognitive tests such as the paced serial addition test (PASAT 3' form A), auditory verbal learning test (AVLT), divided attention (test battery for the assessment of attention, TAP), alertness (TAP), verbal learning test (VLT, Viennese test system), and non-verbal learning test (NVLT, Viennese test system). To keep conditions constant we used no parallel versions.
The main fields of our study were therefore memory, attention, and mood. Computer-based testing was used for maximum objectivity and reliability. Statistical evaluation was done using an ANOVA for dependent variables on a commercially available product (IBM SPSS statistics 19). Error probability was set at p ^ 0.05.
Results
Many of the parameters tested showed significant improvements (NVLT, alertness, two SF-36 subscales [rolephysical, general health], BDI II, physical and mental fatigue, AVLT reproduction trials), the remainder was stable (divided attention, VLT, PASAT, other SF-36 subscales, AVLT recognition, phasic alertness). Altogether, 15 out of 30 parameters improved significantly, 15 remained equal, and none deteriorated. Examples are given in the figures.
A full display of results is given in table 2 . Since not all tests could be given at all times to all patients, the number of available tests per time point varied between 29 and 20. Using a Bonferroni correction for multiple measurements, the final level of significance was set at 0.0017. Significant results based on this criterion are given in bold face.
Discussion
MS results in motor, cognitive, and neuropsychiatric symptoms in a significant number of patients, all of which can occur independently of each other. Common cognitive symptoms include deficits in complex atten- tion, efficiency of information processing, executive functioning, processing speed, and long-term memory [9] . Other neurobehavioral and neuropsychological functions such as mood or mental well-being are also involved.
Studies on the effect of basic immunomodulatory treatment are very heterogeneous. In one study, a significant beneficial effect of interferon beta-1a was shown for processing speed, learning, and memory; interferon beta1b has shown some mild benefit, whereas glatiramer acetate showed no significant effect so far. It is believed that the effect of immunomodulatory drugs on cognition is mediated by their impact on brain inflammation. This may be the reason for the observation that it needs some time to develop a beneficial effect.
In our study, we observed the development of cognitive and neurobehavioral functions of patients treated with natalizumab, which is considered a very effective and fast-acting immunomodulatory agent. We could show that an effect on cognition was already present after 6 months of treatment.
Our results are in line with a recent study using brief cognitive tests to monitor impairments in patients with MS such as show up on a symbol digit modalities test (SDMT) and a MS neuropsychological screening questionnaire (MSNQ). The application of these tests has demonstrated the reliability and feasibility of short psychometric assessments as a monitoring tool for cognition over time [10] . Following a cohort of 713 patients over 48 weeks, mild but steady improvements were shown in the SDMT while the MSNQ -indicating cognitive problems -decreased at the same time.
This tendency was confirmed by our study. Of six cognitive tests applied, four improved, while two remained stable and none deteriorated. Of three questionnaires assessing subjective health, well-being and quality of life, two improved and one remained stable displaying a tendency for improvement. At the same time, the neurological outcome was favorable, since with one exception nobody experienced a relapse during the observation period. It has been demonstrated in turn that an elective interruption of natalizumab treatment after 24 months for 2-6 months resulted in a clinical relapse rate of 19% and an increased MRI activity in 47.4% [11] . Therefore, a sustained and regular therapy is advisable for an extended clinical effect and prevention of relapse.
Our findings are in agreement with a recent preliminary study in 17 patients presenting with a mean EDSS of 5 using a different test battery [12] and spanning a period of 1 year. Here, too, improvements were shown in memory and executive functions.
Although learning effects cannot be excluded in our study since no parallel test versions and no matched control group were available, the generally favorable outcome is strongly indicative of a positive influence on attention, memory, mood and subjective well-being. An ANOVA for dependent samples yielded significant differences comparing the first and last assessments for non-verbal learning, verbal reproduction, alertness, depression, fatigue, and working memory. Phasic alertness, i.e. the extent to which a warning signal adds to attentional performance, remained stable. The fields where no significant improvements were found were verbal recognition memory, divided attention, and most parameters of functional health.
These results emerged although the patients had formerly been treated with various other drugs without satisfying results, suffered from their disease for a mean of more than 10 years and showed a moderate disease severity (EDSS 3.5).
Summing up, natalizumab seems to be a promising treatment option for MS patients not only with regard to relapse prevention and neurological impairment, but also for cognitive and emotional functions.
Since this was an open-label prospective study, further work is necessary to prove whether this regime is superior to no or intermittent treatment or to treatment with other disease-modifying or immunomodulatory regimens. 
